Company DescriptionPaxman AB (publ), together with its subsidiaries, develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment in Europe, the United States, Mexico, Japan, Oceania, rest of Asia, and South and Central America. It serves various cancer centers and hospitals. The comapny has a research collaboration agreement with National University Hospital, Singapore for the development of portable cooling and compression device. Paxman AB (publ) was founded in 1996 and is based in Karlshamn, Sweden.

How the Company Makes Money

Paxman AB Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
253.01M	210.12M	156.75M	96.20M	78.05M
	Gross Profit
175.42M	146.42M	101.44M	64.52M	50.69M
	EBIT
33.51M	12.62M	-1.22M	-10.57M	-11.69M
	EBITDA
49.73M	31.23M	16.18M	2.90M	-1.04M
	Net Income Common Stockholders
40.20M	8.33M	-10.32M	-12.78M	-19.19M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
40.31M	24.98M	38.09M	72.27M	3.58M
	Total Assets
227.23M	167.12M	173.96M	166.34M	77.01M
	Total Debt
14.29M	13.57M	16.98M	17.15M	48.23M
	Net Debt
-26.02M	-11.41M	-21.11M	-55.11M	44.65M
	Total Liabilities
63.24M	44.51M	59.76M	40.59M	66.12M
	Stockholders Equity
163.99M	122.62M	114.20M	125.75M	10.89M
Cash Flow		Free Cash Flow
15.99M	-9.70M	-33.01M	-27.94M	-14.80M
	Operating Cash Flow
39.10M	15.63M	2.69M	-4.14M	-8.48M
	Investing Cash Flow
-24.50M	-25.33M	-36.69M	-24.45M	-6.32M
	Financing Cash Flow
721.00K	-3.41M	-169.00K	97.28M	16.78M

Paxman AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (54)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PXMBF		$165.16M	32.96	10.01%	―	―	―
Sector *	54 Neutral	$5.31B	3.28	-45.10%	2.80%	16.76%	0.02%
DIZTF		$20.25M	―	-440.28%	―	―	―
24C		€104.66M	35.92	10.11%	―	―	―
6IRA		€33.47M	―	-194.31%	―	―	―
5YL		€35.98M	―	-33.54%	―	―	―
7D2A		€109.77M	―	-5.61%	―	―	―

* Healthcare Sector Average

Performance Comparison

PXMBF

Paxman AB

3.50

0.00

0.00%

DIZTF

Dignitana AB

0.21

0.06

40.00%

DE:24C

C-Rad AB Class B

2.98

-0.84

-21.99%

DE:6IRA

IRLAB Therapeutics AB Class A

0.64

-0.60

-48.39%

DE:5YL

BrainCool AB

0.12

-0.08

-40.00%

DE:7D2A

Sedana Medical AB

1.06

-1.23

-53.71%

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.